MediWound Ltd - Asset Resilience Ratio
MediWound Ltd (M8W) has an Asset Resilience Ratio of 56.04% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how MediWound Ltd's Asset Resilience Ratio has changed over time. Check asset allocation strategy of MediWound Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down MediWound Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see M8W market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €48.34 Million | 56.04% |
| Total Liquid Assets | €48.34 Million | 56.04% |
Asset Resilience Insights
- Very High Liquidity: MediWound Ltd maintains exceptional liquid asset reserves at 56.04% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MediWound Ltd Industry Peers by Asset Resilience Ratio
Compare MediWound Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for MediWound Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for MediWound Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 56.04% | €48.34 Million ≈ $56.52 Million |
€86.25 Million ≈ $100.84 Million |
+9.78pp |
| 2024-12-31 | 46.27% | €34.01 Million ≈ $39.76 Million |
€73.50 Million ≈ $85.92 Million |
+1.62pp |
| 2023-12-31 | 44.65% | €29.68 Million ≈ $34.69 Million |
€66.46 Million ≈ $77.70 Million |
-- |
| 2022-12-31 | 0.00% | €0.00 ≈ $0.00 |
€50.02 Million ≈ $58.47 Million |
-- |
| 2021-12-31 | 0.00% | €0.00 ≈ $0.00 |
€19.74 Million ≈ $23.08 Million |
-- |
| 2020-12-31 | 12.95% | €4.02 Million ≈ $4.70 Million |
€31.07 Million ≈ $36.32 Million |
-41.34pp |
| 2019-12-31 | 54.29% | €22.04 Million ≈ $25.76 Million |
€40.59 Million ≈ $47.45 Million |
+6.33pp |
| 2018-12-31 | 47.96% | €16.92 Million ≈ $19.78 Million |
€35.28 Million ≈ $41.24 Million |
-- |
| 2017-12-31 | 0.00% | €0.00 ≈ $0.00 |
€44.13 Million ≈ $51.60 Million |
-- |
| 2016-12-31 | 3.25% | €1.16 Million ≈ $1.36 Million |
€35.76 Million ≈ $41.81 Million |
-- |
About MediWound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn cen… Read more